Clarinha Bbb

This PIR volume presents a comprehensive collection of reviews that focus on the role of the blood-brain barrier (BBB) during steady-state and inflamed conditions. Within the central nervous system (CNS)

The development of new CNS drugs is notoriously difficult. Drugs must reach CNS target sites for action and these sites are protected by a number of barriers, the most important being the blood–brain barrier (BBB). Many factors are therefore critical to consider for CNS drug delivery, e.g.

Evolving technologies starting with tracer studies, and more recently with genomics and proteomics, have provided novel information about the molecular properties of cerebral endothelium and astrocytes; however, further studies must be done in animal models of neurological diseases and in humans to get a clearer understanding of the pathogenesis of blood-brain barrier (BBB) breakdown in nervous system diseases.

Evolving technologies starting with tracer studies, and more recently with genomics and proteomics, have provided novel information about the molecular properties of cerebral endothelium and astrocytes; however, further studies must be done in animal models of neurological diseases and in humans to get a clearer understanding of the pathogenesis of blood-brain barrier (BBB) breakdown in nervous system diseases.